Exploring the Frontiers of Neoadjuvant Therapy for Lung Cancer: a Prospective Observational Real-world Study

Recruiting now

Conditions studied: Lung Cancer

In brief

Lung cancer is a malignant tumor with the highest incidence and mortality rate of cancer patients worldwide. Traditional treatments for lung cancer include surgery, radiotherapy and chemotherapy, etc. Although the growth and spread of the tumor can be controlled to a certain extent, the cure rate for patients with progressive stage is still low and the prognosis is poor. Neoadjuvant therapy intends to use chemotherapy, immunotherapy, and targeted therapy to reduce the size and load of the tumor before surgery, to improve the surgical resection rate and therapeutic effect. 1. Primary research objective: to explore the therapeutic efficacy of patients with different characteristics under different neoadjuvant therapeutic regimens. 2. Secondary objectives To investigate the strengths and weaknesses of different neoadjuvant regimens in real-world clinical practice, and to investigate the long-term outcomes of patients treated with different regimens.

Key facts

Study ID

NCT06216782

Run by

Shanghai Pulmonary Hospital, Shanghai, China

People needed

2000

Starts

2023-12-16

Expected to finish

2033-12-30

Last updated by the study team

2024-01-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age greater than or equal to 18 years;
• Pathohistologically confirmed diagnosis of non-small cell lung cancer or small cell lung cancer;
• Received neoadjuvant therapy after diagnosis;
• Written informed consent.

You may not qualify if…

• Patients enrolled in other clinical trials;
• Patients refused enrollment in this study;
• Patients refused follow-up.

Where it is running

• Shanghai Pulmonary Hospital — Shanghai, Shanghai Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.